Reintervention and Survival After Limited Lung Resection for Lung Cancer Treatment in Australia

Tran, Bich; Sedrakyan, Art; Flynn, P.W.; Altorki, Nasser K.; Jorm, Louisa; Wright, Gavin

doi:10.1016/j.athoracsur.2018.11.045

Cited by 3 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regional variation in 2-year mortality for NSCLC has been demonstrated where those with timely first definitive treatment (OR 0.73; 95% CI 0.56 to 0.94) and multidisciplinary meeting presentation (OR 0.74; 95% CI 0.59 to 0.93) were significantly less likely to die within 2 years of diagnosis 19. Variation in processes of care is evident in timeliness of care,20–22 pathological confirmation of diagnosis,23 utilisation of multidisciplinary meetings23 24 (figure 2), patterns of care delivery25–28 and follow-up after cancer treatment 29. Substantial variation is also evident in key outcomes of care including the utilisation of active anticancer treatment17 23 30–32 and survival 19 32 33…”

Section: Introductionmentioning

confidence: 99%

Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry: a protocol paper

et al. 2022

View full text Add to dashboard Cite

IntroductionLung cancer is the leading cause of cancer mortality, comprising the largest national cancer disease burden in Australia and New Zealand. Regional reports identify substantial evidence-practice gaps, unwarranted variation from best practice, and variation in processes and outcomes of care between treating centres. The Australia and New Zealand Lung Cancer Registry (ANZLCR) will be developed as a Clinical Quality Registry to monitor the safety, quality and effectiveness of lung cancer care in Australia and New Zealand.Methods and analysisPatient participants will include all adults >18 years of age with a new diagnosis of non-small-cell lung cancer (NSCLC), SCLC, thymoma or mesothelioma. The ANZLCR will register confirmed diagnoses using opt-out consent. Data will address key patient, disease, management processes and outcomes reported as clinical quality indicators. Electronic data collection facilitated by local data collectors and local, state and federal data linkage will enhance completeness and accuracy. Data will be stored and maintained in a secure web-based data platform overseen by registry management. Central governance with binational representation from consumers, patients and carers, governance, administration, health department, health policy bodies, university research and healthcare workers will provide project oversight.Ethics and disseminationThe ANZLCR has received national ethics approval under the National Mutual Acceptance scheme. Data will be routinely reported to participating sites describing performance against measures of agreed best practice and nationally to stakeholders including federal, state and territory departments of health. Local, regional and (bi)national benchmarks, augmented with online dashboard indicator reporting will enable local targeting of quality improvement efforts.

show abstract